Everest Medicines launched its first research center for innovative medicines in Feb. 2022 in Shanghai’s Zhangjiang Hi-Tech Park. The center, covering an area of 1,730 square meters, enhances Everest Medicines’ drug discovery capabilities and develop a pipeline of potentially first-in-class or best-in-class drugs to meet unmet medical needs.

Everest is developing multiple self-discovery projects in renal diseases and leveraging our mRNA platform. In the renal space, the company has a promising discovery pipeline with the potential to treat glomerular diseases and the most advanced program is expected to enter clinical trials in 2024. Using our clinically validated mRNA platform, Everest will drive development of preventive and therapeutic vaccines against various infectious diseases and cancers. Among them, the mRNA rabies vaccine program has achieved pre-clinical proof-of-concept.